

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office\ Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/787,350	02/26/2004	Bryce M. Harvey	47221-00003	4869
759	90 02/11/2005		EXAM	INER
C. Brandon Browning, Esq.			COE, SUSAN D	
Sirote & Permutt, P.C. P.O. Box 55727			ART UNIT	PAPER NUMBER
Birmingham, AL 35255-5727			1654	
			DATE MAILED: 02/11/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	<u> </u>	
	Application No.	Applicant(s)
	10/787,350	HARVEY ET AL.
Office Action Summary	Examiner	Art Unit
	Susan D. Coe	1654
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl If NO period for reply is specified above, the maximum statutory period or Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time y within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE!	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).
Status	•	
1) Responsive to communication(s) filed on		
2a) This action is FINAL . 2b) This	action is non-final.	
3) Since this application is in condition for allowated closed in accordance with the practice under E		
Disposition of Claims		
 4) Claim(s) 1-66 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-66 are subject to restriction and/or 	wn from consideration.	
Application Papers		
9)☐ The specification is objected to by the Examine		
10)☐ The drawing(s) filed on is/are: a)☐ acc		
Applicant may not request that any objection to the	= : :	
Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Ex		
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage
Attachment(s)		
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail Da	
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 	🗂	Patent Application (PTO-152)

DETAILED ACTION

1. Claims 1-66 are currently pending. Please take notice of the election of species requirement beginning at paragraph 3. To be fully responsive, applicant must fulfill this requirement.

Election/Restrictions

- 2. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-18 and 22-63, drawn to a dietary supplement, classified in class 424, subclass 725.
 - II. Claims 19 and 65, drawn to a method for treating or preventing prostate disease, classified in class 424, subclass 725.
 - III. Claims 20 and 65, drawn to a method for treating or preventing vascular disease, classified in class 424, subclass 725.
 - IV. Claims 21 and 66, drawn to a method for treating or preventing prostate and vascular disease, classified in class 424, subclass 725.

The inventions are distinct, each from the other because of the following reasons:

Inventions I is related to inventions II-IV as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used for a different purpose, such as using folic acid to help prevent birth defects.

Application/Control Number: 10/787,350

Art Unit: 1654

Inventions II, III, and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions. Each of the inventions treats a different patient. Patient one has prostate disease. Patient two has vascular disease. Patient three has both disease. Since the patients for each method of treatment do not have to be the same patient, this shows that the inventions are distinct.

Because these inventions are distinct for the reasons given above and the search required for one groups is not required for the other groups, restriction for examination purposes as indicated is proper.

3. This application contains claims directed to the following patentably distinct species of the claimed invention:

A: specific dietary supplement encompassed by the claims. Applicant's claims are drawn to numerous embodiments of the supplement composition. Applicant must indicate specific ingredients for examination by either indicating a claim which encompasses the selected ingredients or by listing the desired ingredients with an identifier if the ingredients should "comprise," "consist essentially of" or "consist of" the elected ingredients. Applicant must be specific in the ingredients selected if an elected claim contains alternatively listed ingredients.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, no claims are generic.

Application/Control Number: 10/787,350

Art Unit: 1654

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1654

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Susan Coe whose telephone number is (571) 272-0963. The examiner can normally be reached on Monday to Thursday from 8:00 to 5:30 and on alternating Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, can be reached on (571) 272-0974. The official fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding can be directed to the receptionist whose telephone number is (571) 272-1600.

2-9-05

Assan D be

Susan D. Coe Primary Examiner Art Unit 1654